1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Sumitovant Biopharma Acquires Urovant Sciences

M&A Deal Summary

Sumitovant Biopharma Acquires Urovant Sciences

On November 12, 2020, Sumitovant Biopharma acquired life science company Urovant Sciences for 584M USD

Acquisition Highlights
  • This is Sumitovant Biopharma’s 1st transaction in the Life Science sector.
  • This is Sumitovant Biopharma’s largest (disclosed) transaction.
  • This is Sumitovant Biopharma’s 1st transaction in the United States.
  • This is Sumitovant Biopharma’s 1st transaction in California.

M&A Deal Summary
Date 2020-11-12
Target Urovant Sciences
Sector Life Science
Buyer(s) Sumitovant Biopharma
Deal Type Add-on Acquisition
Deal Value 584M USD
Advisor(s) Lazard (Financial)
O'Melveny & Myers (Legal)

Target

Urovant Sciences

Irvine, California, United States
Urovant Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant Sciences is based in Irvine, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Sumitovant Biopharma

New York, New York, United States
Category Company
Sector Life Science
DESCRIPTION

Sumitovant Biopharma, Inc. is a global biopharmaceutical company. Sumitovant Biopharma is based in New York.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2020 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal